

Date Required: \_\_\_\_\_ Ship To:  Patient  MD Office  Other: \_\_\_\_\_

| PATIENT INFORMATION  | PRESCRIBER INFORMATION    |
|--|---------------------------|
| Patient Name: _____  | Prescriber Name: _____    |
| Address: _____   | Address: _____            |
| City, State, Zip: _____  | City, State, Zip: _____   |
| Home Phone: _____  | Phone: _____              |
| Cell Phone: _____  | Fax: _____                |
| Date of Birth: _____ <input type="checkbox"/> Male <input type="checkbox"/> Female | DEA #: _____ NPI #: _____ |
| Emergency Contact: _____ Phone: _____  | Contact Person: _____     |

**INSURANCE INFORMATION (Please attach the front and back of insurance and prescription drug card.)**

|                            |           |                       |
|----------------------------|-----------|-----------------------|
| Primary Insurance: _____   | ID: _____ | Group: _____          |
| Secondary Insurance: _____ | ID: _____ | Group: _____          |
| Prescription Card: _____   | ID: _____ | BIN: _____ PCN: _____ |

**To better serve your patient and facilitate insurance authorization, please complete the pertinent sections:**

**PATIENT DIAGNOSIS/CLINICAL INFORMATION**

|  |   |
|--|---|
| <input type="checkbox"/> J45.909 Asthma, Unspecified<br><input type="checkbox"/> L20.9 Atopic Dermatitis<br><input type="checkbox"/> L50.1 Chronic Idiopathic Urticaria<br><input type="checkbox"/> J45.40 Moderate Persistent Asthma, uncomplicated<br><input type="checkbox"/> J45.41 Moderate Persistent Asthma w/ acute exacerbation<br><input type="checkbox"/> J33.0 Polyp of Nasal Cavity<br><input type="checkbox"/> D86.9 Sarcoidosis, unspecified<br><input type="checkbox"/> Other: _____ | Weight: _____ <input type="checkbox"/> kg <input type="checkbox"/> lbs    Height: _____ <input type="checkbox"/> cm <input type="checkbox"/> in    %BSA: _____<br>Allergies: _____ <input type="checkbox"/> NKDA<br>Injection Training/Home Health RN visit is necessary. <input type="checkbox"/> Yes <input type="checkbox"/> No<br>Site of Care: <input type="checkbox"/> Home <input type="checkbox"/> MD Office <input type="checkbox"/> Other: _____<br>Eosinophil count _____ cells/uL    IgE Levels _____    Date of Test _____<br>Number of exacerbations in the last 12 months _____<br><input type="checkbox"/> Patient is not a candidate for surgery    Rationale: _____ |
|--|---|

**PRESCRIPTION INFORMATION**

| Medication   | Dose/Strength   | Instructions   | Quantity                         | Refills |
|--|---|--|----------------------------------|---------|
| Dupixent®<br>(dupilumab)   | <input type="checkbox"/> 200 mg/1.14 mL prefilled syringe<br>2 pack   | <input type="checkbox"/> <b>Starter Dose:</b> Administer two syringes (total of 400 mg) subcutaneously on Day 1 then one syringe (200 mg) every two weeks starting on Day 15 thereafter<br><input type="checkbox"/> <b>Maintenance Dose:</b> Administer 200mg subcutaneously every two weeks   | <input type="checkbox"/> 2       |         |
|  | <input type="checkbox"/> 300 mg/2 mL prefilled syringe<br>2 pack  | <input type="checkbox"/> <b>Starter Dose:</b> Administer two syringes (total of 600 mg) subcutaneously on Day 1 then one syringe (300 mg) every two weeks starting on Day 15 thereafter<br><input type="checkbox"/> <b>Maintenance Dose:</b> Administer 300mg subcutaneously every two weeks   | <input type="checkbox"/> 2       |         |
|  |   | <input type="checkbox"/> Inject 300 mg subcutaneously every other week **Dosing intended for chronic rhinosinusitis with nasal polyposis (CRSwNP)**  |                                  |         |
| Fasenra™<br>(benralizumab)   | <input type="checkbox"/> 30mg PFS<br><input type="checkbox"/> 30mg Autoinjector   | <input type="checkbox"/> <b>Starter Dose:</b> Administer 30mg subcutaneously every 4 weeks for the first 3 doses, followed by once every 8 weeks thereafter<br><input type="checkbox"/> <b>Maintenance Dose:</b> Administer 30mg subcutaneously every 8 weeks  |                                  |         |
| Nucala®<br>(mepolizumab)   | <input type="checkbox"/> 100mg vial<br><input type="checkbox"/> 100mg PFS<br><input type="checkbox"/> 100mg Autoinjector    | <input type="checkbox"/> Inject 100mg subcutaneously once every 4 weeks into the upper arm, thigh, or abdomen <b>Supplies:</b><br>• 1 sterile water for injection (10ml) for every vial of Nucala dispensed<br>• 1-ml polypropylene syringe with 21-to 27-G x 0.5-inch needle for subcutaneous injection<br>• Alcohol swabs • 3 mL Luer Lock injection syringe • NDL 21G needle for reconstitution<br>Send quantity sufficient for medication days supply.<br><input type="checkbox"/> No supplies (The above supplies will be sent with shipment unless indicated). | <input type="checkbox"/> 28 days |         |
| Xolair®<br>(Omalizumab)<br><br><input type="checkbox"/> Asthma<br><input type="checkbox"/> CIU | <input type="checkbox"/> 75mg PFS<br><input type="checkbox"/> 150mg PFS<br><input type="checkbox"/> 150 mg single dose vial | Every 4 week dosing: <input type="checkbox"/> Administer 75 mg dose subcutaneously every 4 weeks<br><input type="checkbox"/> Administer 150 mg dose subcutaneously every 4 weeks<br><input type="checkbox"/> Administer 300 mg dose subcutaneously every 4 weeks<br><input type="checkbox"/> Other: Administer _____ mg per dose subcutaneously every 4 weeks  |                                  |         |
|  |   | Every 2 week dosing: <input type="checkbox"/> Administer 75 mg dose subcutaneously every 2 weeks<br><input type="checkbox"/> Administer 150 mg dose subcutaneously every 2 weeks<br><input type="checkbox"/> Administer 300 mg dose subcutaneously every 2 weeks<br><input type="checkbox"/> Other: Administer _____ mg per dose subcutaneously every 2 weeks  |                                  |         |
|  |   | <input type="checkbox"/> <b>Supplies:</b><br>• 1 vial sterile water for injection (10 mL vial) for every vial of Xolair dispensed<br>• NDL 25G x 5/8" Safety Glide needle for subcutaneous injection<br>• Alcohol swabs • Flexible bandages 1" x 3"<br>• 3 mL Luer Lock injection syringe • NDL 18G x 1 & 1/2" Safety Glide needle for reconstitution<br>Send quantity sufficient for medication days supply.<br><input type="checkbox"/> No supplies (The above supplies will be sent with shipment unless indicated).  |                                  |         |

**Prescriber Signature: \_\_\_\_\_ Date: \_\_\_\_\_**